Wall Street analyst estimates for Alector, Inc. (ALEC): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 3 |
| Sell | 2 |
| Strong Sell | 0 |
| Total analysts | 14 |
| Avg rating (1-5) | 0.50 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-05 | $-0.24 | ||
| 2026-08-06 | $-0.21 | $-0.23 | +8.1% |
| 2026-05-07 | $-0.21 | $-0.35 | +40.0% |
| 2026-02-25 | $-0.34 | $-0.39 | +12.8% |
| 2025-11-06 | $-0.34 | $-0.42 | +19.0% |
| 2025-08-07 | $-0.30 | $-0.45 | +33.3% |
| 2025-05-08 | $-0.41 | $-0.44 | +6.8% |
| 2025-02-26 | $-0.02 | $-0.61 | +96.7% |
Valuation Ratios
| Price / Book | -18.68 |
| EV / EBITDA | -1.95 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $416000 | $3.7M | $27.7M | $21.2M | $21.1M | $207.1M | $133.6M | $97.1M | $100.6M | $21.0M |
| Cost of Revenue | $13.7M | $29.9M | $73.0M | $100.5M | $156.9M | $189.4M | 0 | $8.8M | $185.9M | $9.7M |
| Gross Profit | -$13.3M | -$26.2M | -$45.4M | -$79.3M | -$135.8M | $17.7M | $133.6M | $88.2M | -$85.4M | $11.4M |
| Research & Development | $13.7M | $29.9M | $73.0M | $100.5M | $156.9M | $189.4M | $210.4M | $192.1M | $209.2M | $123.1M |
| Selling, General & Admin | $1.9M | $6.5M | $11.9M | $33.9M | $59.4M | $55.0M | $61.0M | $56.7M | $57.4M | $54.0M |
| Operating Expenses | $15.5M | $36.4M | $85.0M | $35.1M | $59.4M | $55.0M | $271.5M | $240.0M | $59.6M | $157.2M |
| Operating Income | -$15.1M | -$32.7M | -$57.3M | -$114.4M | -$195.2M | -$37.4M | -$137.8M | -$151.7M | -$145.0M | -$145.8M |
| EBITDA | -$14.9M | -$32.0M | -$56.3M | -$109.5M | -$187.9M | -$28.0M | -$121.6M | -$116.3M | -$110.1M | -$133.1M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$15.1M | -$32.5M | -$52.2M | -$105.4M | -$190.2M | -$36.3M | -$130.1M | -$125.2M | -$118.9M | -$142.8M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | $3.3M | $5.2M | $128000 | $168000 |
| Net Income | -$15.1M | -$32.5M | -$52.2M | -$105.4M | -$190.2M | -$36.3M | -$133.3M | -$130.4M | -$119.0M | -$142.9M |
| EPS | $-1.78 | $-0.63 | $-0.76 | $-1.62 | $-2.45 | $-0.45 | $-1.62 | $-1.56 | $-1.23 | $-1.39 |
| EPS (Diluted) | $-1.78 | $-0.63 | $-0.76 | $-1.62 | $-2.45 | $-0.45 | $-1.62 | $-1.56 | $-1.23 | $-1.39 |
| Shares Outstanding (Diluted) | $8.5M | $51.2M | $68.4M | $61.7M | $77.8M | $80.4M | $82.5M | $83.7M | $96.6M | $103.0M |
Price
| Price | $1.93 |
| Market Cap | $214M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABOS · APLT · CRBP · FATE · IRD · MOLN · NKTX
Explore sector: Healthcare · Biotechnology
More sections of ALEC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks